Press Releases Viatris Inc.

Equities

VTRS

US92556V1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.57 ^USD	+0.87%		+2.84%	+6.83%

Apr. 18	Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	MT
Apr. 18	UK Regulator to Consider Undertakings for Theramex-Viatris Deal	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Viatris to Report First Quarter 2024 Financial Results on May 9, 2024	Apr. 16	PR
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	Apr. 15	AQ
Viatris Appoints Corinne Le Goff as Chief Commercial Officer	Apr. 15	PR
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada	Apr. 15	AQ
Pharma deal could reduce choice and lead to higher prices for HRT treatments	Apr. 04	AQ
Viatris Announces the Launch of RYZUMVl 0.75% in the United States	Apr. 02	AQ
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris	Apr. 01	AQ
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline	Mar. 27	PR
Viatris : Statement Regarding the Transaction with Insud Pharma	Mar. 12	PU
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris	Mar. 11	PR
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris	Mar. 11	BU
Viatris: Q4 Earnings Snapshot	Feb. 28	AQ
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance	Feb. 28	PR
Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results	Feb. 05	PR
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference	Dec. 21	PR
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer	Dec. 15	PR
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders	Dec. 15	PR
Acquisition deal to back European biosimilars market	Nov. 30	AQ
Viatris Partners With Comfort Cases to Support Youth in U.S. Foster Care	Nov. 22	AQ
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease	Nov. 14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Viatris Inc.

Equities

VTRS

US92556V1061

Press Releases

Filters